AMEX:STXS

Stock Analysis Report

Executive Summary

Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally.


Snowflake Analysis

Flawless balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Stereotaxis's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: STXS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

10.4%

STXS

1.6%

US Medical Equipment

0.9%

US Market


1 Year Return

174.2%

STXS

22.1%

US Medical Equipment

20.0%

US Market

Return vs Industry: STXS exceeded the US Medical Equipment industry which returned 22.1% over the past year.

Return vs Market: STXS exceeded the US Market which returned 20.1% over the past year.


Shareholder returns

STXSIndustryMarket
7 Day10.4%1.6%0.9%
30 Day-18.4%1.0%1.4%
90 Day13.3%7.8%8.8%
1 Year174.2%174.2%23.1%22.1%22.5%20.0%
3 Year564.1%564.1%84.0%78.8%49.9%40.3%
5 Year53.4%53.4%117.3%94.6%73.2%54.1%

Price Volatility Vs. Market

How volatile is Stereotaxis's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Stereotaxis undervalued compared to its fair value and its price relative to the market?

12.44x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate STXS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate STXS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: STXS is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: STXS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate STXS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: STXS is overvalued based on its PB Ratio (12.4x) compared to the US Medical Equipment industry average (4.1x).


Next Steps

Future Growth

How is Stereotaxis forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.0%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Stereotaxis has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Stereotaxis performed over the past 5 years?

8.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: STXS is currently unprofitable.

Growing Profit Margin: STXS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: STXS is unprofitable, but has reduced losses over the past 5 years at a rate of 8.5% per year.

Accelerating Growth: Unable to compare STXS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: STXS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (7.1%).


Return on Equity

High ROE: STXS has a negative Return on Equity (-14.2%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Stereotaxis's financial position?


Financial Position Analysis

Short Term Liabilities: STXS's short term assets ($38.0M) exceed its short term liabilities ($11.2M).

Long Term Liabilities: STXS's short term assets ($38.0M) exceed its long term liabilities ($3.4M).


Debt to Equity History and Analysis

Debt Level: STXS is debt free.

Reducing Debt: STXS currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Inventory Level: STXS has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if STXS's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: STXS has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: STXS has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 16.4% each year


Next Steps

Dividend

What is Stereotaxis's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate STXS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate STXS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if STXS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if STXS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of STXS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

David Fischel (32yo)

3yrs

Tenure

US$58,500

Compensation

Mr. David Leo Fischel, CFA, CPA has been the Chairman of Stereotaxis, Inc. since February 3, 2017 and has been its Chief Executive Officer since February 3, 2017. Mr. Fischel is a Principal and primary por ...


Leadership Team

NamePositionTenureCompensationOwnership
David Fischel
CEO & Chairman3yrsUS$58.50k0.030% $85.0k
Kevin Barry
Chief Legal Officer1.3yrsUS$218.67kno data
Kimberly Peery
Chief Financial Officer0.3yrsno data0.0050% $14.1k
Gery Tomassoni
Chief Medical Officer7.5yrsno datano data
J. Burkhardt
Chief Development Advisor12.1yrsno datano data

3.0yrs

Average Tenure

Experienced Management: STXS's management team is considered experienced (3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
David Fischel
CEO & Chairman3yrsUS$58.50k0.030% $85.0k
Arun Menawat
Independent Director3.4yrsUS$58.50k0.50% $1.4m
Joseph Kiani
Independent Director3.4yrsUS$58.50k9.34% $26.2m
Robert Messey
Independent Director14.8yrsUS$58.50k0.18% $492.2k
Nathan Fischel
Director3yrsUS$58.50k0.030% $85.0k
David Benfer
Lead Independent Director5yrsUS$58.50k0.38% $1.1m
Ross Levin
Independent Director1.7yrsUS$39.48kno data

3.4yrs

Average Tenure

63yo

Average Age

Experienced Board: STXS's board of directors are considered experienced (3.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 41.5%.


Top Shareholders

Company Information

Stereotaxis, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Stereotaxis, Inc.
  • Ticker: STXS
  • Exchange: AMEX
  • Founded: 1990
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$280.841m
  • Shares outstanding: 66.08m
  • Website: https://www.stereotaxis.com

Number of Employees


Location

  • Stereotaxis, Inc.
  • 4320 Forest Park Avenue
  • Suite 100
  • St. Louis
  • Missouri
  • 63108
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
STXSAMEX (NYSE MKT LLC)YesCommon SharesUSUSDAug 2004

Biography

Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally. Its products include Niobe ES robotic magnetic navigation system that enables physicians to complete interventional procedures by providing image guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and Vdrive system, which offers navigation and stability for the diagnostic and therapeutic devices designed to enhance interventional procedures. The company also offers Odyssey solution, a real-time information solution to manage, control, record, and share procedures across networks. In addition, it provides disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company’s disposables and other accessories include V-CAS and V-CAS Deflect catheter advancement systems; and V-loop circular and V-Sono ICE catheter manipulators. The company markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was founded in 1990 and is headquartered in St. Louis, Missouri. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/17 23:58
End of Day Share Price2020/02/14 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.